Inflammation-induced synergetic enhancement of nanoparticle treatments with DOXIL® and 90Y-Lactosome for orthotopic mammary tumor
Source abstract
Abstract
Polymeric micelles (Lactosome) in the size of 20–30 nm were labeled with radionuclides of 111In (111In-DOTA-Lactosome) for SPECT imaging and 90Y (90Y-DOTA-Lactosome) for β-ray irradiation for mammary tumor in mice. The tumor site at the femoral right leg grafted with 4T1 cells was clearly imaged at 24 h after the intravenous injection. Biodistribution revealed that the half-life time of 111In-DOTA-Lactosome was 11 h, which enabled the nanoparticle selectively accumulated in tumor site due to the enhanced permeability and retention (EPR) effect. The anti-tumor therapeutic effect of 90Y-DOTA-Lactosome was observed depending on the dose frequency and amount. Under the condition of the percutaneous ethanol injection treatment, the therapeutic effect of 90Y-DOTA-Lactosome was enhanced due to the super EPR effect. Owing to the super EPR effect, co-administration of 90Y-DOTA-Lactosome and DOXIL® inhibited the tumor growth during 15 days with their administrations.
Source: openaire · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: Nanoparticle-Based Drug Delivery · Nanoplatforms for cancer theranostics · Radiopharmaceutical Chemistry and Applications
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (26)
Show source-provided references
1. Abu Lila AS, Kiwada H, Ishida T (2013) The accelerated blood clearance (ABC) phenomenon: clinical challenge and approaches to manage. J Control Release 172:38–47. doi: 10.1016/j.jconrel.2013.07.02610.1016/j.jconrel.2013.07.026 ↗
2. Del Vecchio S, Zanneti A, Fonti R, Pace L, Salvatore M (2007) Nuclear imaging in cancer theranostics. Q J Nucl Med Mol Imaging 51:152–163
3. Fang J, Nakamura H, Maeda H (2011) The EPR effect: unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect. Adv Drug Deliv Rev 63:136–151. doi: 10.1016/j.addr.2010.04.00910.1016/j.addr.2010.04.009 ↗
4. Goldsmith SJ (2010) Radioimmunotherapy of lymphoma: Bexxar and zevalin. Semin Nucl Med 40:122–135. doi: 10.1053/j.semnuclmed.2009.11.00210.1053/j.semnuclmed.2009.11.002 ↗
5. Hara E, Makino A, Kurihara K, Yamamoto F, Ozeki E, Kimura S (2012) Pharmacokinetic change of nanoparticulate formulation “lactosome” on multiple administrations. Int Immunopharmacol 14:261–266. doi: 10.1016/j.intimp.2012.07.01110.1016/j.intimp.2012.07.011 ↗
6. Hara E, Makino A, Kurihara K, Sugai M, Shimizu A, Hara I, Ozeki E, Kimura S (2013a) Evasion from accelerated blood clearance of nanocarrier named as “lactosome” induced by excessive administration of lactosome. Biochim Biophys Acta 1830:4046–4052. doi: 10.1016/j.bbagen.2013.03.02410.1016/j.bbagen.2013.03.024 ↗
7. Hara E, Makino A, Kurihara K, Ueda M, Hara I, Kawabe T, Yamamoto F, Ozeki E, Togashi K, Kimura S (2013b) Radionuclide therapy using nanoparticle of 131I-lactosome in combination with percutaneous ethanol injection therapy. J Nanopart Res. doi: 10.1007/s11051-013-2131-2
8. Hara E, Ueda M, Kim CJ, Makino A, Hara I, Ozeki E, Kimura S (2014a) Suppressive immune response of poly-(sarcosine) chains in peptide-nanosheets in contrast to polymeric micelles. J Pept Sci 20:570–577. doi: 10.1002/psc.265510.1002/psc.2655 ↗
9. Hara E, Ueda M, Makino A, Hara I, Ozeki E, Kimura S (2014b) Factors influencing in vivo disposition of polymeric micelles on multiple administrations. ACS Med Chem Lett 5:873–877. doi: 10.1021/ml500112u10.1021/ml500112u ↗
10. Kamaly N, Xiao Z, Valencia PM, Radovic-Moreno AF, Farokhzad OC (2012) Targeted polymeric therapeutic nanoparticles: design, development and clinical translation. Chem Soc Rev 41:2971–3010. doi: 10.1039/c2cs15344k10.1039/c2cs15344k ↗
11. Kim CJ, Hara E, Shimizu A, Sugai M, Kimura S (2015) Activation of b1a cells in peritoneal cavity by t cell-independent antigen expressed on polymeric micelle. J Pharm Sci 104:1839–1847. doi: 10.1002/jps.2439710.1002/jps.24397 ↗
12. Makino A, Yamahara R, Ozeki E, Kimura S (2007) Preparation of novel polymer assemblies, “lactosome”, composed of poly(l-lactic acid) and poly(sarcosine). Chem Lett 36:1220–1221. doi: 10.1246/cl.2007.122010.1246/cl.2007.1220 ↗
13. Makino A, Kizaka-Kondoh S, Yamahara R, Hara I, Kanzaki T, Ozeki E, Hiraoka M, Kimura S (2009) Near-infrared fluorescence tumor imaging using nanocarrier composed of poly(l-lactic acid)-block-poly(sarcosine) amphiphilic polydepsipeptide. Biomaterials 30:5156–5160. doi: 10.1016/j.biomaterials.2009.05.04610.1016/j.biomaterials.2009.05.046 ↗
14. Makino A, Hara E, Hara I, Yamahara R, Kurihara K, Ozeki E, Yamamoto F, Kimura S (2012) Control of in vivo blood clearance time of polymeric micelle by stereochemistry of amphiphilic polydepsipeptides. J Control Release 161:821–825. doi: 10.1016/j.jconrel.2012.05.00610.1016/j.jconrel.2012.05.006 ↗
15. Makino A, Hara E, Hara I, Ozeki E, Kimura S (2014) Size control of core-shell-type polymeric micelle with a nanometer precision. Langmuir 30:669–674. doi: 10.1021/la404488n10.1021/la404488n ↗
16. Matsumura Y, Maeda H (1986) A new concept for macromolecular therapeutics in cancer-chemotherapy—mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res 46:6387–6392
17. Ministry of Health LaWoJ (2015) Annual Health, Labour and Welfare Report 2013–2014
18. Parveen S, Misra R, Sahoo SK (2012) Nanoparticles: a boon to drug delivery, therapeutics, diagnostics and imaging. Nanomedicine 8:147–166. doi: 10.1016/j.nano.2011.05.01610.1016/j.nano.2011.05.016 ↗
19. Sano K, Nakajima T, Choyke PL, Kobayashi H (2013) Markedly enhanced permeability and retention effects induced by photo-immunotherapy of tumors. ACS Nano 7:717–724. doi: 10.1021/nn305011p10.1021/nn305011p ↗
20. Sano K, Nakajima T, Choyke PL, Kobayashi H (2014) The effect of photoimmunotherapy followed by liposomal daunorubicin in a mixed tumor model: a demonstration of the super-enhanced permeability and retention effect after photoimmunotherapy. Mol Cancer Ther 13:426–432. doi: 10.1158/1535-7163.mct-13-063310.1158/1535-7163.MCT-13-0633 ↗
21. Shimizu Y, Temma T, Hara I, Makino A, Yamahara R, E-i Ozeki, Ono M, Saji H (2014) Micelle-based activatable probe for in vivo near-infrared optical imaging of cancer biomolecules. Nanomedicine 10:187–195. doi: 10.1016/j.nano.2013.06.00910.1016/j.nano.2013.06.009 ↗
22. Swaika A, Hammond WA, Joseph RW (2015) Current state of anti-PD-L1 and anti-PD-1 agents in cancer therapy. Mol Immunol 67:4–17. doi: 10.1016/j.molimm.2015.02.00910.1016/j.molimm.2015.02.009 ↗
23. Tsukanishi T, Funayama T, Ozeki E, Hara I, Abe T, Onishi S, Yamazaki M, Sakane M (2014) Indocyanine green-lactosome and near-infrared light-based intraoperative imaging and photodynamic therapy for metastatic bone tumors. J Photopolym Sci Technol 27:449–45210.2494/photopolymer.27.449 ↗
24. Xie J, Lee S, Chen X (2010) Nanoparticle-based theranostic agents. Adv Drug Deliv Rev 62:1064–1079. doi: 10.1016/j.addr.2010.07.00910.1016/j.addr.2010.07.009 ↗
25. Yamamoto S, Mizota Y (2015) Rainbow of KIBOU (ROK) study: a breast cancer survivor cohort in Japan. Ann Oncol 26:3410.1093/annonc/mdv428.02 ↗
26. Yamamoto F, Yamahara R, Makino A, Kurihara K, Tsukada H, Hara E, Hara I, Kizaka-Kondoh S, Ohkubo Y, Ozeki E, Kimura S (2013) Radiosynthesis and initial evaluation of 18F labeled nanocarrier composed of poly(l-lactic acid)-block-poly(sarcosine) amphiphilic polydepsipeptide. Nucl Med Biol 40:387–394. doi: 10.1016/j.nucmedbio.2012.12.00810.1016/j.nucmedbio.2012.12.008 ↗